In a significant regulatory shift impacting the supplement and chemical research industries, the U.S. Drug Enforcement Administration (DEA) has officially moved to place several synthetic alkaloids associated with Mitragyna speciosa—commonly known as kratom—under the restrictive umbrella of Schedule I of the Controlled Substances Act (CSA).
The move, formalized in late August 2026, represents an aggressive attempt by federal authorities to curb the "proliferation" of high-potency, semi-synthetic derivatives that have increasingly appeared on the market. While the DEA emphasizes that these measures are temporary and intended to address an "imminent hazard to public safety," the decision creates a complex new compliance landscape for researchers, manufacturers, and distributors.
The Main Facts: Defining the Scope of the Order
On August 25, 2026, the DEA finalized a temporary scheduling order designating three specific synthetic substances as Schedule I controlled substances: mitragynine pseudoindoxyl, MGM-15, and MGM-16.
This decision followed a series of Federal Register notices published earlier in July, which outlined the agency’s intent to address the rising popularity of these substances. According to the DEA, these chemicals are not merely traditional kratom extracts; they are sophisticated, laboratory-synthesized compounds that possess potent opioid-like effects.
Under the CSA, Schedule I is reserved for substances that meet three specific criteria:
- A high potential for abuse.
- No currently accepted medical use in treatment in the United States.
- A lack of accepted safety for use under medical supervision.
The DEA’s order dictates that this classification applies to the substances themselves, as well as their isomers, esters, ethers, and salts. Consequently, any individual or entity wishing to manufacture, distribute, import, export, or conduct research on these compounds must now possess a Schedule I registration. Failure to comply with these federal regulations subjects violators to severe administrative, civil, and criminal sanctions.
A Chronology of Federal Intervention
The path to this scheduling decision was characterized by rapid administrative action and inter-agency coordination between the DEA, the Department of Health and Human Services (HHS), and the Food and Drug Administration (FDA).
- July 1, 2026: The DEA published two critical notices in the Federal Register. The first signaled the intent to place mitragynine pseudoindoxyl, MGM-15, and MGM-16 under Schedule I. The second notice proposed setting a threshold for 7-hydroxymitragynine (7-OH), a naturally occurring alkaloid in kratom, to determine when it crosses the line into regulated territory.
- July 6, 2026: The official notices were codified in the Federal Register, triggering a 30-day public comment period.
- August 2026: The Office of the Assistant Secretary for Health (OASH) reviewed public submissions and provided input to the Attorney General. The Attorney General, having delegated the scheduling authority to the DEA Administrator, authorized the final order.
- August 25, 2026: The DEA issued the final temporary scheduling order for the three synthetic substances, effective immediately.
- September 10, 2026: The extended deadline for public comments regarding the proposed thresholds for 7-hydroxymitragynine.
Supporting Data: Why the DEA Identified an "Imminent Hazard"
The justification for the DEA’s intervention is rooted in extensive pharmacological data suggesting that these substances pose a threat comparable to traditional illicit opioids.
The Shift to Synthetic Potency
The DEA noted a disturbing evolution in the kratom marketplace. While historical use involved raw botanical leaf, the market has shifted toward standardized, high-potency, semi-synthetic products. Mitragynine pseudoindoxyl, for example, is a chemical rearrangement of 7-OH, while MGM-15 is a synthetic derivative. MGM-16, the 9-fluoro derivative of mitragynine pseudoindoxyl, is noted for its extreme opioid potency.
Pharmacological Profiles
Preclinical studies analyzed by the DEA revealed that these substances demonstrate a powerful affinity for the mu-opioid receptor (MOR). In laboratory models, mitragynine pseudoindoxyl was found to be approximately 100 times more potent than mitragynine. Furthermore, MGM-15 and MGM-16 were identified as being 50 to 240 times more potent than morphine. These substances are associated with classic opioid risks, including respiratory depression, physical dependence, and psychological addiction.
Marketing and Public Health Risks
The DEA highlighted that these substances were being marketed with deceptive advertising. Consumers were often misled into believing these products offered benefits like "mental clarity," "reduced restlessness," or "internal calm," while being encouraged to view them as natural supplements. The use of "fruity flavors" and chewable formats further lowered the barrier to entry, particularly for younger or unsuspecting demographics. Data suggests that as of 2022, there were approximately 2 million users of these types of products, creating a significant public health footprint.
Official Responses and Regulatory Ambiguity
The process has not been without its challenges, particularly regarding the definitions used in the proposed scheduling of 7-OH.
The DEA’s proposal to regulate products containing more than 0.050% of 7-hydroxymitragynine has caused concern due to the ambiguity of the term "article." The DEA did not define this term in its notices, and it remains undefined in the Controlled Substances Act. Legal experts, including those from the legal community specializing in FDA and DEA compliance, have noted that the lack of clarity regarding whether "article" refers to a "finished product" or a "single unit dosage" could lead to significant compliance difficulties for manufacturers.
The OASH has opened a public docket to address these specific concerns, explicitly asking stakeholders for input on the threshold levels for 7-OH. It is important to note that this comment period does not invite debate on the general utility or safety of kratom as a whole; rather, it is narrowly focused on the feasibility and precision of the DEA’s proposed threshold metrics.
Implications for Stakeholders
The immediate effect of the August 25 order is a complete cessation of commercial sales for products containing mitragynine pseudoindoxyl, MGM-15, and MGM-16.
For Retailers and Distributors
Retailers must immediately pull products containing these synthetic substances from their shelves. Because these are now Schedule I substances, they cannot be sold to the general public under any circumstances. Businesses that currently hold stock of these items must comply with federal protocols for disposal or surrender.
For Researchers
The landscape for scientific study has fundamentally changed. Researchers who previously studied these substances must now obtain a Schedule I registration from the DEA. This involves rigorous security requirements, extensive record-keeping, and strict oversight. The DEA confirmed that as of the date of the order, there were no approved New Drug Applications (NDAs) or Investigational Drug Applications (INDs) for these substances, reinforcing the lack of recognized medical utility.
For the Kratom Industry
It is critical to distinguish that this order specifically targets synthetic alkaloids and products containing concentrated 7-OH beyond the proposed thresholds. The DEA has signaled that it is not, at this time, scheduling botanical kratom leaf itself. However, the industry remains in a state of high alert. The "temporary" nature of this scheduling lasts for two years, with the possibility of a one-year extension. During this period, the DEA will likely continue to evaluate whether permanent scheduling is required.
Conclusion: A New Era of Oversight
The DEA’s move against synthetic kratom-related substances marks a pivotal moment in the regulation of the supplement industry. By treating these compounds with the same severity as potent synthetic opioids, the federal government has signaled that it will no longer tolerate the "gray market" sale of designer drugs marketed under the guise of botanical wellness.
For those involved in the manufacture and distribution of kratom products, the message is clear: the era of unregulated semi-synthetic additives is ending. Compliance, rigorous testing, and a deep understanding of the evolving legal thresholds are now the only paths forward. As the comment period for 7-OH thresholds closes, the industry must prepare for a future defined by increased scrutiny and a higher burden of proof regarding the safety and chemical composition of their products.
Disclaimer: This report is for informational purposes only and does not constitute legal advice. Stakeholders are encouraged to consult with qualified legal counsel regarding compliance with the Controlled Substances Act and the Federal Food, Drug, and Cosmetic Act.
About the Author
